Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Capital Expenditures (2021 - 2024)

InMed Pharmaceuticals' Capital Expenditures history spans 4 years, with the latest figure at $2.0 for Q1 2024.

  • For Q1 2024, Capital Expenditures changed N/A year-over-year to $2.0; the TTM value through Jun 2024 reached $31818.0, up 117.77%, while the annual FY2024 figure was $9293.0, 94.19% down from the prior year.
  • Capital Expenditures reached $2.0 in Q1 2024 per INM's latest filing, down from $31816.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $250000.0 in Q3 2021 to a low of -$214445.0 in Q4 2021.
  • Average Capital Expenditures over 4 years is $14185.2, with a median of $3553.0 recorded in 2022.